Replies

We are ALMOST ready to do something about it now.

think about it, Bush has known for sometime of Saddam's involvement,
and right when the bombs start dropping he will let everyone know the truth.
Then all those leftist will crap their shorts because they were against a war with Iraq.
Just my thoughts on the issue,

Hey Saddam the bombing starts in two weeks.

Anyone suggesting Iraq was involved in WTC I, WTC II-9/11, or the Anthrax letters (we won't even get near OKC or Flight FILLINTHENUMBERS) will immediately be labelled a KOOK. All respectible media reports prove otherwise. Case closed. The Iraq Adventure is Bush's highly risky and political attempt to stay in power after stealing the White House, yada, yada, yada...

If Iraq WERE shown to be guilty of collusion to directly attack American interests (Anthrax Anthrax Anthrax...) then that would mean - gosh - Bush, Cheney, and (ohmygod) Rumsfeld were Right! That would be UnAcceptable. At least at the NYT/WP/CNN/Etc.

>ALMOST ready

Not for commercial use. Solely to be used for the educational purposes of research and open discussion.

ANTHRAX: DoD contract awarded to develop immunostimulatory oligos to enhance vaccines
Bio-Terrorism.Info
EXPANDED REPORTING; Pg. 4
January 13, 2003

Coley Pharmaceutical Group announced that the U.S. Defense Advanced Research Projects Agency (DARPA) has awarded $6MM to Coley to support the development of Coley's CpG immunostimulatory oligonucleotides (oligos) to enhance anthrax vaccines.

"This contract builds on our preclinical data showing that CpG oligos protect mice against a broad range of pathogens, including anthrax, as well as our human clinical data showing enhancement of the Engerix-B Hepatitis B vaccine when combined with our immunostimulatory oligos," said Robert L. Bratzler, PhD, Coley president and CEO. "The DARPA contract and other development agreements with our partners, including Aventis and GlaxoSmithKline, give Coley the opportunity to realize the full potential of its immunostimulatory oligos to prevent or treat a broad range of diseases." The current anthrax vaccine requires six doses and 18 months to produce immunity. Coley's CpG oligos, used together with vaccines, have the potential to reduce the number of vaccine doses, induce protective antibody levels more quickly, produce higher affinity antibodies directed against a broader range of anthrax antigens, and to improve duration of protection.

This research at Coley stems from a grant awarded in 1999 to Arthur Krieg, MD, then a professor of Internal Medicine at the University of Iowa, a Coley founder and currently the company's Chief Scientific Officer. Commenting on this new contract, Krieg said, "I am delighted that our progress since we began this program in 1999 has been so rapid, and that DARPA has selected this program to transition from the preclinical phase to the clinical phase as a high priority."

Coley has specifically optimized CpG 10103, a B Class oligo for vaccine applications. CpG 10103, acting through the TLR9 receptor present in B-cells and plasmacytoid dendritic cells, potently stimulates human B-cell proliferation, enhances antigen-specific antibody production and induces Interferon-alpha production, Interleukin-10 secretion, and Natural Killer Cell (NK cell) activity. These broad immunostimulatory actions are required to improve the immune response to vaccines.

Almost 60% of subjects given the vaccine together with CpG 7909 had protective antibody levels within just 2 weeks of the first dose, and 100% of subjects receiving CpG 7909 did within 6 weeks.

CpG 7909, Coley's lead drug candidate, is also a B Class oligo. CpG 7909 significantly increased antibody responses when administered to normal human volunteers in combination with Engerix-B, GlaxoSmithKline's marketed prophylactic Hepatitis B vaccine.

The approved dosing of Engerix-B requires three vaccinations over 6 months but fails to induce protective antibody levels in 5-10% of normal healthy individuals. In a clinical study conducted by Coley in normal healthy volunteers, individuals given the Engerix-B vaccine (without CpG 7909) rarely had any detectable antibody response within 2 weeks of the first vaccine dose, but almost 60% of subjects given the vaccine together with CpG 7909 had protective antibody levels within just 2 weeks of the first dose, and 100% of subjects receiving CpG 7909 did within 6 weeks.

This article was prepared by Bio-Terrorism.Info editors from staff and other reports.

http://www.NewsRx.net